Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-28)

In this article we will discuss Durvalumab (Warnings-28)

In this article, we will discuss Durvalumab (Warnings-28). So, let’s get started.

Other Immune-Mediated Adverse Reactions

  • The following clinically significant, immune-mediated adverse reactions occurred at an incidence of less than 1% each in patients who received Durvalumab or were reported with the use of other PD-1/PD-L1 blocking antibodies.
  • Cardiac/vascular: Myocarditis, pericarditis, vasculitis.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.